Literature DB >> 19529921

Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia.

Xiang Yang Zhang1, Da Chun Chen, Ling Yan Qi, Fang Wang, Mei Hong Xiu, Song Chen, Gui Ying Wu, Therese A Kosten, Thomas R Kosten.   

Abstract

OBJECTIVE: Despite extensive use of antipsychotic drug treatment, few studies address the prevalence of tardive dyskinesia (TD) in homogeneous ethnic groups such as the Chinese. This study examined gender-specific relationships between TD and symptom levels in schizophrenia among Han Chinese, which have previously received little systematic study.
MATERIALS AND METHODS: Five hundred and twenty-two inpatients with schizophrenia receiving long-term treatment with antipsychotics were evaluated with the AIMS. The patient's psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS). Demographic and clinical data were collected from a detailed questionnaire and medical records.
RESULTS: The overall TD prevalence was 33.7% with rates of 39.2% (138/352) in males and 22.4% (38/170) in females (chi (2) = 14.6, df = 1, p < 0.0001; adjust odds ratio 2.06; CI, 1.32-3.16). The AIMS score in patients with TD was lower in females than males (5.3 +/- 3.9 vs 6.7 +/- 3.7, t = 2.52, p < 0.01) after adjustment for the significant covariates. TD was associated with the negative symptoms on the PANSS in both genders, and with age, PANSS total and positive symptoms in men, not women.
CONCLUSION: Our present findings suggest that there are gender differences in the prevalence, risk, and clinical correlates of TD in schizophrenia. Although this study is limited by cross-sectional designs, the magnitude of these gender-specific differences is substantial and deservers further prospective study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19529921     DOI: 10.1007/s00213-009-1590-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  49 in total

1.  Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures.

Authors:  O Yuen; M P Caligiuri; R Williams; R A Dickson
Journal:  Br J Psychiatry       Date:  1996-06       Impact factor: 9.319

2.  Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao extrapyramidal syndromes study V.

Authors:  Peter N van Harten; Hans W Hoek; Glenn E Matroos; Jim van Os
Journal:  J Clin Psychiatry       Date:  2006-12       Impact factor: 4.384

3.  The prevalence of tardive dyskinesia.

Authors:  M G Woerner; J M Kane; J A Lieberman; J Alvir; K J Bergmann; M Borenstein; N R Schooler; S Mukherjee; J Rotrosen; M Rubinstein
Journal:  J Clin Psychopharmacol       Date:  1991-02       Impact factor: 3.153

Review 4.  The treatment of tardive dyskinesia--a systematic review and meta-analysis.

Authors:  K V Soares; J J McGrath
Journal:  Schizophr Res       Date:  1999-08-23       Impact factor: 4.939

Review 5.  Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.

Authors:  J M Kane; J M Smith
Journal:  Arch Gen Psychiatry       Date:  1982-04

6.  Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong.

Authors:  H Chiu; P Shum; J Lau; L Lam; S Lee
Journal:  Am J Psychiatry       Date:  1992-08       Impact factor: 18.112

7.  Abnormal movements in never-medicated Indian patients with schizophrenia.

Authors:  R G McCreadie; R Thara; S Kamath; R Padmavathy; S Latha; N Mathrubootham; M S Menon
Journal:  Br J Psychiatry       Date:  1996-02       Impact factor: 9.319

Review 8.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

9.  Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

Authors:  D V Jeste; M P Caligiuri; J S Paulsen; R K Heaton; J P Lacro; M J Harris; A Bailey; R L Fell; L A McAdams
Journal:  Arch Gen Psychiatry       Date:  1995-09

10.  Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia.

Authors:  P F Liddle; T R Barnes; J Speller; D Kibel
Journal:  Br J Psychiatry       Date:  1993-12       Impact factor: 9.319

View more
  5 in total

1.  Possible association between DBH 19 bp insertion/deletion polymorphism and clinical symptoms in schizophrenia with tardive dyskinesia.

Authors:  Li Hui; Mei Han; Xu Feng Huang; Min Jie Ye; Ke Zheng; Jin Cai He; Meng Han Lv; Bao Hua Zhang; Jair C Soares; Xiang Yang Zhang
Journal:  J Neural Transm (Vienna)       Date:  2014-10-22       Impact factor: 3.575

2.  Management of common adverse effects of antipsychotic medications.

Authors:  T Scott Stroup; Neil Gray
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

3.  Rater evaluations for psychiatric instruments and cultural differences: the positive and negative syndrome scale in China and the United States.

Authors:  Neil Krishan Aggarwal; Xiang Yang Zhang; Elina Stefanovics; Da Chun Chen; Mei Hong Xiu; Ke Xu; Robert A Rosenheck
Journal:  J Nerv Ment Dis       Date:  2012-09       Impact factor: 2.254

Review 4.  Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Authors:  Nicki Niemann; Joseph Jankovic
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

5.  Genome wide study of tardive dyskinesia in schizophrenia.

Authors:  Keane Lim; Max Lam; Clement Zai; Jenny Tay; Nina Karlsson; Smita N Deshpande; B K Thelma; Norio Ozaki; Toshiya Inada; Kang Sim; Siow-Ann Chong; Todd Lencz; Jianjun Liu; Jimmy Lee
Journal:  Transl Psychiatry       Date:  2021-06-08       Impact factor: 6.222

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.